tetano
Editor, Senior Moderator
Clin Infect Dis. 2010 Apr 23. [Epub ahead of print]
Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus.
Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, Domm J, Denison MR, Chappell JD.
Departments of 1Pediatrics, 2Pathology, and 3Microbiology and Immunology, Vanderbilt University School of Medicine and the Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee.
Abstract
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.
PMID: 20415572 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20415572
Use of Intravenous Zanamivir after Development of Oseltamivir Resistance in a Critically Ill Immunosuppressed Child Infected with 2009 Pandemic Influenza A (H1N1) Virus.
Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, Domm J, Denison MR, Chappell JD.
Departments of 1Pediatrics, 2Pathology, and 3Microbiology and Immunology, Vanderbilt University School of Medicine and the Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee.
Abstract
Immunosuppressed patients receiving oseltamivir for 2009 novel H1N1 influenza A infection may develop drug resistance, leading to treatment failure. Intravenous zanamivir was administered on a compassionate-use basis to a profoundly immunosuppressed pediatric patient with severe oseltamivir-resistant novel H1N1 pneumonia. The regimen was well tolerated and was associated with a decrease in viral burden.
PMID: 20415572 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20415572